Literature DB >> 16785570

Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.

Yang Liu1, Sean Daley, Viktoria N Evdokimova, David D Zdobinski, Douglas M Potter, Lisa H Butterfield.   

Abstract

We identified a series of immunodominant and subdominant epitopes from alpha fetoprotein (AFP), restricted by HLA-A*0201, which are recognized by the human T cell repertoire. The four immunodominant epitopes have been tested for immunogenicity in vivo, in HLA-A*0201+AFP+ advanced stage hepatocellular cancer (HCC) patients, and have activated and expanded AFP-specific IFN-gamma-producing T cells in these patients, despite high serum levels of this self Ag. Here, we have examined the frequency, function, and avidity of the T cells specific for subdominant epitopes from AFP. We find that T cells specific for several of these epitopes are of similar or higher avidity than those specific for immunodominant epitopes. We then tested the peripheral blood of subjects ex vivo with different levels of serum AFP for the hierarchy of response to epitopes from this Ag and find that HCC patients have detectable frequencies of circulating IFN-gamma-producing AFP-specific CD8+ T cells to both immunodominant and subdominant epitopes. We find the immunodominant and subdominant peptide-specific T cells to be differentially expanded with different modes of Ag presentation. Whereas spontaneous and AFP protein-stimulated responses show evidence for immunodominance, AdVhAFP-transduced dendritic cell-stimulated responses were broader and not skewed. Importantly, these data identify subdominant epitopes from AFP that can activate high-avidity T cells, and that can be detected and expanded in HCC subjects. These subdominant epitope-specific T cells can also recognize tumor cells and may be important therapeutically.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785570      PMCID: PMC3607814          DOI: 10.4049/jimmunol.177.1.712

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.

Authors:  W S Meng; L H Butterfield; A Ribas; V B Dissette; J B Heller; G A Miranda; J A Glaspy; W H McBride; J S Economou
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.

Authors:  L H Butterfield; W S Meng; A Koh; C M Vollmer; A Ribas; V B Dissette; K Faull; J A Glaspy; W H McBride; J S Economou
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

3.  Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

Authors:  Jun Lu; Esteban Celis
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

4.  Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.

Authors:  W S Meng; L H Butterfield; A Ribas; J B Heller; V B Dissette; J A Glaspy; W H McBride; J S Economou
Journal:  Mol Immunol       Date:  2000-11       Impact factor: 4.407

5.  Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses.

Authors:  Lana Schumacher; Antoni Ribas; Vivian B Dissette; William H McBride; Bijay Mukherji; James S Economou; Lisa H Butterfield
Journal:  J Immunother       Date:  2004 May-Jun       Impact factor: 4.456

6.  Activation of an alpha-fetoprotein/receptor pathway in human normal and malignant peripheral blood mononuclear cells.

Authors:  C Esteban; J Trojan; A Macho; Z Mishal; C Lafarge-Frayssinet; J Uriel
Journal:  Leukemia       Date:  1993-11       Impact factor: 11.528

7.  T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

Authors:  Lisa H Butterfield; Antoni Ribas; Wilson S Meng; Vivian B Dissette; Saral Amarnani; Huong T Vu; Elisabeth Seja; Karen Todd; John A Glaspy; William H McBride; James S Economou
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

8.  High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

Authors:  David-Alexandre Gross; Stéphanie Graff-Dubois; Paule Opolon; Sébastien Cornet; Pedro Alves; Annelise Bennaceur-Griscelli; Olivier Faure; Philippe Guillaume; Hüseyin Firat; Salem Chouaib; François A Lemonnier; Jean Davoust; Isabelle Miconnet; Robert H Vonderheide; Kostas Kosmatopoulos
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

9.  Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.

Authors:  Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Jan Mueller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

10.  Proliferating dendritic cell progenitors in human blood.

Authors:  N Romani; S Gruner; D Brang; E Kämpgen; A Lenz; B Trockenbacher; G Konwalinka; P O Fritsch; R M Steinman; G Schuler
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  25 in total

1.  Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.

Authors:  Yang Liu; Lisa H Butterfield; Xiaohui Fu; Zhenshun Song; Xiaoping Zhang; Chongde Lu; Guanghui Ding; Mengchao Wu
Journal:  Int J Oncol       Date:  2011-04-13       Impact factor: 5.650

2.  Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.

Authors:  C Cubillos-Zapata; E Guzman; A Turner; S C Gilbert; H Prentice; J C Hope; B Charleston
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 3.  Immunotherapy of hepatocellular carcinoma.

Authors:  Bruno Sangro; Daniel Palmer; Ignacio Melero
Journal:  Hepat Oncol       Date:  2014-12-11

4.  Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.

Authors:  Yoshito Tomimaru; Sasmita Mishra; Howard Safran; Kevin P Charpentier; William Martin; Anne S De Groot; Stephen H Gregory; Jack R Wands
Journal:  Vaccine       Date:  2015-01-25       Impact factor: 3.641

5.  Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Authors:  Jennifer N Uram; Chelsea M Black; Emilee Flynn; Lanqing Huang; Todd D Armstrong; Elizabeth M Jaffee
Journal:  J Immunol       Date:  2011-02-23       Impact factor: 5.422

6.  Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1).

Authors:  Peiyuan Li; Qiang Du; Zongxian Cao; Zhong Guo; John Evankovich; Wei Yan; Ying Chang; Lifang Shao; Donna Beer Stolz; Allan Tsung; David A Geller
Journal:  Cancer Lett       Date:  2011-10-01       Impact factor: 8.679

7.  Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.

Authors:  Zhenjuan Li; Haiping Gong; Qiuping Liu; Wanli Wu; Jianting Cheng; Yingyi Mei; Yaolong Chen; Hongjun Zheng; Xiaohong Yu; Shi Zhong; Yi Li
Journal:  Immunology       Date:  2020-01-10       Impact factor: 7.397

8.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

9.  Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.

Authors:  Jodi L Yorty; Satvir S Tevethia; Todd D Schell
Journal:  Cancer Immunol Immunother       Date:  2007-11-15       Impact factor: 6.968

10.  Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.

Authors:  S Behboudi; A Alisa; S Boswell; J Anastassiou; A A Pathan; R Williams
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.